Asthma is a rapidly growing global concern
Chronic disease is now the leading cause of death and disability throughout the world. Many chronic diseases, including asthma, allergy, obesity, diabetes, autism and others, exhibit a similar pattern of alarmingly rapid increases in prevalence associated with modernization. Our microbiome-based therapeutics and diagnostics are aimed at the prevention and treatment of these diseases, beginning with asthma and allergy.
Preventing allergic disease before it starts
Current standard of care treatments such as antihistamines, steroids, bronchodilators and biologics, target the downstream inflammation that results from an inappropriate immune response. In contrast, Siolta Therapeutic’s microbiome-based approach towards allergic asthma aims to prevent the initiation of the immune dysfunction cascade, thus preventing allergic disease before it starts. Our preclinical proof of concept studies provide evidence that oral supplementation with our lead product has the potential to alter the gut microbiome, reprogram metabolism, reduce immune activation, and thus protect against allergic inflammation.
Asthma is just the beginning
Strong evidence supports the role of the early-life infant gut microbiome in establishing proper immune function. Accordingly, early-life disruptions to the gut microbiome are associated with an increased risk of numerous chronic diseases. Our unique platform is designed to address multiple targets across the chronic disease landscape in a rapid and iterative manner. With clinical studies underway for allergic disease, we are now broadening our focus to include other indications such as obesity and diabetes.See Our Pipeline